In our previous studies, a strain of the nonpathogenic, anaerobic, intestinal bacterium, Bifidobacterium longum (B. longum), was found to be localized selectively and to proliferate within solid tumors after systemic administration. In addition, B. longum transformed with the shuttle-plasmid encoding the cytosine deaminase (CD) gene expressed active CD, which deaminated the prodrug 5-fluorocytosine (5-FC) to the anticancer agent 5-fluorouracil (5-FU). We also reported antitumor efficacy with the same plasmid in several animal experiments. In this study, we constructed a novel shuttleplasmid, pAV001-HU-eCD-M968, which included the mutant CD gene with a mutation at the active site to increase the enzymatic activity.
In our previous studies, a strain of the nonpathogenic, anaerobic, intestinal bacterium, Bifidobacterium longum (B. longum), was found to be localized selectively and to proliferate within solid tumors after systemic administration. In addition, B. longum transformed with the shuttle-plasmid encoding the cytosine deaminase (CD) gene expressed active CD, which deaminated the prodrug 5-fluorocytosine (5-FC) to the anticancer agent 5-fluorouracil (5-FU). We also reported antitumor efficacy with the same plasmid in several animal experiments. In this study, we constructed a novel shuttleplasmid, pAV001-HU-eCD-M968, which included the mutant CD gene with a mutation at the active site to increase the enzymatic activity.
In addition, the plasmid-transformed B. longum produces mutant CD and strongly increased (by 10-fold) its 5-FC to 5-FU enzymatic activity. The use of B. longum harboring the new shuttle-plasmid increases the effectiveness of our enzyme/prodrug strategy.
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Anaerobic bacteria can live and grow in hypoxicnecrotic regions of solid tumors, 1) and this is highly tumor-specific since these hypoxic-necrotic regions are not present in normal tissues.
2) It is possible that localization of the bacteria, which express enzymes used in conventional enzyme/prodrug therapy, might activate a non-toxic prodrug to a chemotherapeutic drug specifically at the tumor site. Recently, some groups reported cancer therapy strategies using genetically modified bacteria. Attenuated Salmonella was very successful in both animal experiments [3] [4] [5] and in clinical trials, 6) and another group using Clostridium also reported a promising synergistic effect on host immune response. [7] [8] [9] [10] Such bacteria are clearly powerful tools for cancer therapy, but they are toxic in themselves.
What is important in the therapy for cancer patients is to assure its safety as well as its efficacy. Bifidobacterium is a nonpathogenic and domestic bacterium, which is known as a probiotic species. In addition, its safety was also confirmed in a previous study by Kimura et al. 11) indicating no significant pathological changes in body weight, peripheral leukocyte counts, body temperature, fur condition, or lifespan in mice, hamsters, guinea pigs, or rabbits following i.v. administration of B. longum. Moreover, Sasaki et al. 12) reported that B. longum 105A is entirely nonpathogenic and nonanaphylactogenic by intravenous injection into guinea pigs. Thus, it is possible that genetically engineered Bifidobacterium expressing therapeutic genes may be available as vectors for tumor-specific gene delivery systems.
Enzyme/prodrug therapy is being developed as a treatment for cancer and other pathological conditions.
13) The cytosine deaminase/5-fluorocytosine strategy is one of most widely tested enzyme/prodrug strategies in both animal models and clinical trials. [14] [15] [16] Cytosine deaminase (CD) (EC 3.5.4.1) is an enzyme found in many bacteria and fungi, but not in mammalian cells which do not ordinarily metabolize cytosine to uracil. CD has the ability to deaminate the nontoxic y To whom correspondence should be addressed. Tel: +81-263-37-2656; Fax: +81-263-37-2721; E-mail: minoru1@hsp.md.shinshu-u.ac.jp Abbreviations: CD, cytosine deaminase; B. longum, Bifidobacterium longum; 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; amp r , ampicillin resistance gene; AMP, ampicillin; spcm r , spectinomycin resistance gene; SPCM, spectinomycin; oriV, origin of replication; cfu, colony forming unit prodrug 5-fluorocytosine (5-FC) into the highly toxic compound 5-fluorouracil (5-FU), which eventually inhibits DNA synthesis and leads to cell death. 16) Previously, we constructed the plasmid pBLES100-SeCD to adapt enzyme/prodrug therapy to the Bifidobacterial tumor-specific gene delivery system. 17) This plasmid was constructed by inserting the hup promoter 18) and the cytosine deaminase gene into the B. longum-E. coli shuttle-plasmid pBLES100. 19) In addition, we confirmed that B. longum transformed with this plasmid expressed fully active CD 17) and induced cancer recession in chemically induced rat mammary tumors with enzyme/prodrug therapy. 12) This therapeutic strategy is named BifidobactErial Selective Targeting-Cytosine Deaminase (BEST-CD) therapy. 20) Although BEST-CD therapy has been confirmed to be useful in cancer therapy, the anti-tumor efficacy is dependent on the ability of the CD to turn over the prodrug 5-FC, which is an analog of its natural substrate. Mahan et al. 21, 22) showed that 5-FC (K m ¼ 3:3 mM) is a poor substrate for CD compared to its native substrate, cytosine (K m ¼ 0:2 mM) from a kinetic perspective. Hence, in vivo CD enzymatic activity might be occupied by endogenous cytosine. In these papers, it was also demonstrated that additional mutagenesis of aspartic acid residue 314 to alanine in the CD amino acid sequence led to an increase in sensitivity to 5-FC, and also to a decrease in sensitivity to cytosine. Therefore, if CD mutant D314A is incorporated into BEST-CD therapy, its antitumor effect might be more efficacious. In this study, we constructed a novel shuttle-plasmid, pAV001-HU-eCD-M968, which included the mutant CD gene with a mutation at the active site to increase enzymatic activity.
Materials and Methods
Bacterial strains and culture conditions. Bifidobacterium longum 105A was a gift from Dr. Tomotari Mitsuoka (University of Tokyo). The strain was grown in MRS broth (Oxoid, Basingstoke, UK) with 0.02% (w/v) L-cysteine, 0.02% (w/v) sodium ascorbate, and coarse-grained sterile marble (Sigma, Tokyo) at 37 C in an anaerobic system (Mitsubishi Gas Chemical, Tokyo) or plated on BL agar plates (Nissui, Tokyo), and spectinomycin (SPCM, 75 mg/ml) was added in this liquid culture or plate to transform B. longum. For plasmid construction, E. coli JM109 and TOP10 were used. The strains were grown in Luria-Bertani (LB) broth with the appropriate antibiotics at 37 C (250 rpm). In addition, LB plates were prepared by the addition of 1.5% agar (Nissui, Tokyo).
Transformation procedures and plasmid isolation.
Transformation of plasmid DNAs into B. longum was performed by electroporation, as described previously. 19, 23) To isolate the plasmid, a Qiagen Plasmid Mini Kit (Qiagen, Tokyo) was used according to a slightly modified protocol. 24) B. longum was cultured under the above conditions to mid-log phase and then harvested. The cells (about 1:0 Â 10 9 colony forming units, cfu) were washed twice in STE buffer (6.7% saccharose, 50 mM Tris-Cl, pH 8.0, 1 mM EDTA), resuspended with 250 ml of STE, 40 ml of 10% (w/v) lysozyme, and 10 ml of Mutanolysin (20 U; Sigma-Aldrich, St. Louis, MO), and incubated at 37 C for 2 h. The lysates were mixed with P2 buffer from the Qiagen Plasmid Mini Kit, and subsequent procedures were performed according to the manufacturer's protocol. E. coli JM109 was transformed using chemically competent cells obtained by the RbCl method. To isolate plasmid DNA from E. coli, a Qiagen Plasmid Mini Kit (Qiagen) was used, according to the manufacturer's protocol.
Plasmid construction. The plasmids used in this study are listed in Table 1 . A shuttle-plasmid, pBLES100, was constructed by cloning the whole B. longum plasmid pTB6 25) and the gene encoding spectinomycin adenyltransferase (AAD9, spcm r ) from Enterococcus faecalis 26) into the E. coli plasmid pBR322. In addition, pBLES100-S-eCD, which includes the cytosine deaminase gene under the control of the hup promoter in shuttle-plasmid pBLES100, was constructed as described by Nakamura et al. 17) It has been reported that the hup gene, which encodes the histone-like DNA binding protein HU, is highly expressed in B. longum 18) and is thus transcribed from a strong B. longum promoter.
The plasmid pGFPuv carrying the GFPuv gene with a 5 0 MCS (multi-cloning site) and 3 0 MCS, an ampicillin resistance gene (amp r ), and pUC Ori, was purchased from Invitrogen (Tokyo). Plasmid pAV was constructed from pGFPuv. First, to replace the selective marker amp r with spcm r , which functions in both B. longum and E. coli, pGFPuv was digested with Eam1105 I and ScaI, sites for which are located in the ampicillin resistance gene, and ligated with AAD9. In addition, the plasmid was digested with SalI and SpeI, sites for which are located at both ends of the GFPuv gene. The longer fragment, containing pUC Ori, was blunt-ended using a Takara blunting kit (Takara, Tokyo) and then selfligated to yield pAV (Fig. 1A ). E. coli transformed with pAV were confirmed to show resistance to SPCM instead of ampicillin. The cells did not show GFPuv gene expression (data not shown). Almost 1,900 bp of the pTB6 fragment ''rep unit,'' which includes Bifidobacterial ori V and rep B, was ligated into pAV at the ApaI and ScaI sites to make a new shuttle-plasmid, pAV001. The newly constructed shuttle-plasmid was transformed into B. longum 105A by electroporation 19, 23) and the growth of the transformants on BL plates containing SPCM (75 ml/ml) was confirmed (data not shown).
Plasmid pAV001-HU-eCD was constructed with pAV001 and pBLES100-S-eCD (Fig. 1B) . The fragment containing the hup promoter and cytosine deaminase from pBLES100-S-eCD was ligated into the MCS region of pAV001 at the HindIII and SpeI sites. Plasmid pAV001-HU-eCD-M968 was made from pAV001-HUeCD by site-directed mutagenesis of adenine 968 of HUeCD to cytosine according to the manufacturer's protocol, with a QuickChange II Kit (Stratagene, Tokyo).
Western blotting analysis. Wild-type B. longum 105A (WT), pBLES100-S-eCD-transformed B. longum (S-eCD), pAV001-HU-eCD-transformed B. longum (APS001), and pAV001-HU-eCD-M968-transformed B. longum (APS001b) were cultured under the above conditions to log phase (6 h), late-log phase (9 h), and stationary phase (18 h), and then the cell were harvested. The cells (about 1:0 Â 10 9 cfu) were washed twice with STE buffer and resuspended in 1.0 ml of Tris buffer (0.5 M Tris-HCl, pH 8.4, 0.5% w/v TritonX-100, 0.05% w/v protease inhibitor cocktail) (Sigma, Tokyo). The mixture was ultrasonicated for 10 min at 4 C and centrifuged (12,000 rpm, 5 min), and the cleared lysate was stored at À30 C. The lysate protein concentrations were measured by the Lowry method. The same lysates were used for in vitro 5-FC to 5-FU conversion assay.
SDS-polyacrylamide gel electrophoresis was performed according to the method of Laemmli using an ATTO AE-6530, and the lysate samples were adjusted to 0.25 mg of proteins per lane and transferred onto Immun-Blot PVDF membranes (Bio-Rad Laboratories, Tokyo) with a semi-dry blotter (ATTO, Tokyo). The membranes were blocked with BlockAce (Dainippon Pharmaceutical, Osaka, Japan), and incubated with primary antibody (rabbit polyclonal anti-cytosine deaminase; Sawaday Technology, Tokyo). After they were washed with TBS-T buffer, the membranes were incubated with horseradish peroxidase-conjugated antirabbit immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA) as the secondary antibody. The membranes were analyzed with the ECL Western Blot Detection system (Amersham Biosciences, Piscataway, NJ), and then visualized using a Fluo-S-MAX CCD camera detector (Bio-Rad). Densitometric comparisons were performed using a CS analyzer (ATTO). The experiments were performed in triplicate to confirm reproducibility.
Measurement of 5-FC to 5-FU conversion with bacterial incubation. B. longum strains (WT, S-eCD, APS001, and APS001b) were cultured under the above conditions to stationary phase, and then harvested. The cells (about 5:0 Â 10 8 cfu) were washed twice with STE buffer, resuspended in 0.4 ml of MRS broth, and then 1.6 ml of MRS broth supplemented with 0.02% (w/v) L-cysteine, 0.02% (w/v) sodium ascorbate with or without SPCM (75 mg/ml), and 5-FC (50 mM) was added, followed by culture at 37 C under anaerobic conditions. After 0, 1, 2, 4, 8, and 24 h, the culture media were centrifuged, and to the supernatants were immediately added 250 ml of 0.5 M trichloroacetic acid (TCA), and then these were stored at À30 C. The converted 5-FU concentrations of the supernatants were measured by HPLC (Shimadzu, Tokyo). In addition, a viable cell count was also determined on 5 BL agar plates at 0, 2, 4, 8, and 24 h of incubation. The experiments were performed in duplicate or triplicate. A, pGFPuv was digested with Eam1105I and ScaI and ligated with spcm r . In addition, the plasmid was redigested with SalI and SpeI, and the longer fragment was self-ligated as pAV. The Replication unit from pTB6 was ligated into pAV to yield a new shuttle-plasmid, pAV001. B, The Cytosine Deaminase expression shuttle-plasmid pAV001-HU-eCD was constructed from pAV001 and pBLES100-S-eCD. The fragment containing the hup promoter and cytosine deaminase from pBLES100-S-eCD was ligated into pAV001 at the multi-cloning site (HindIII, SpeI). pAV001-HU-eCD-M968 was constructed from pAV001-HU-eCD by site-directed mutagenesis at the 968th Adenine to Cytosine.
In vitro 5-FC to 5-FU conversion assay. B. longum protein lysate samples were prepared under the above conditions. The lysates were adjusted to 5 mg protein/ 250 ml, and 250 ml of 40 mM 5-FC was added at 4 C. Then the mixtures were incubated at 60 C for 20 min, and immediately 250 ml of 0.5 M TCA was added and the mixture was placed on ice for 5 min. The mixtures were centrifuged, and aliquots of the supernatants of approximately 450 ml were added to 150 ml of 0.3 M NaOH and filtrated with 0.45 mm filters before measurement by HPLC.
HPLC conditions. HPLC (Prominence Shimadzu liquid chromatography system) was used to detect 5-FU and 5-FC. The photodiode allay (SPD-M20A, Shimadzu) was used as a detector (5-FU 265 nm; 5-FC 283 nm) and Synergi Hydro-RP (Phenomenex, Tokyo; 4:6 mm Â 15 cm, particle diameter 4 mm) as a column, and the column temperature was 40 C. The mobile phase was 10 mM phosphate, 10 mM sodium dihydrogenphosphate, and 5 mM hexane sulfonic acid, and the flow rate was 1.0 ml/min. Plasmid segregational stability. Plasmid segregational stability in B. longum was studied in continuous subcultures carried out without selective pressure. Plasmid maintenance was estimated by cell counting on BL plates. Samples were subcultured every 24 h with 0.01% seed volume (%2 À10 ) and withdrawn from the cultures on days 0, 1, and 3, diluted, and then plated onto 5 BL plates with and without SPCM. The average numbers of colonies on each BL plate were estimated after anaerobic incubation at 37 C for 2-3 d. The average number of colonies growing on the SPCM plates was expressed as a proportion of the number growing on control plates. This value represented the proportion of B. longum cells harboring the plasmid. The experiments were performed in triplicate, and the average is plotted in Fig. 5 .
Results

Plasmid construction
The plasmids and bacterial strains used are listed in Table 1 . pUC Ori from pUC19 in pGFPuv instead of pBR322-derived ColE1 was selected as the replication origin for the newly constructed shuttle-plasmid pAV001 (Fig. 1A) , because of its advantages with regard to genetic engineering due to the higher copy number in E. coli, 27, 28) but, our shuttle-plasmid reported previously, pBLES100, was constructed based on pBR322. In addition, pAV001 also contained the rep unit, which is the minimum replicon from B. longum plasmid pTB6 suitable for replication in B. longum. 25) Similarly to pBLES100-S-eCD, the hup gene promoter and the CD gene fused to a 9-amino acid region of HU protein at its N-terminal were introduced into pAV001, resulting in pAV001-HU-eCD (Fig. 1B) . Western blotting confirmed that pAV001-HU-eCD-transformed B. longum (designated APS001) expressed CD (data not shown). Based on information reported previously, 21, 22) a mutation, the 314th aspartic acid to alanine, was introduced into pAV001-HU-eCD at the CD active pocket to enhance its enzymatic activity for conversion of 5-FC to 5-FU, generating pAV001-HU-eCD-M968. This plasmid was transformed into B. longum 105A by electroporation 19, 23) and the transformants grew on BL plates containing SPCM (data not shown), and were designated APS001b.
Comparison of CD expression levels
The level of CD expression in B. longum was determined by western blotting analysis (Fig. 2) . Total protein samples at various growth phases were subjected to SDS-PAGE, and the blots were hybridized with anticytosine deaminase antibody. CD signals were detected from B. longum harboring pBLES100-S-eCD (S-eCD), APS001, and APS001b, while no signals were detected from wild-type cells. This result suggests that plasmid reconstruction did not affect CD expression. In addition, this result also suggests that the mutation at CD did not influence the expression level in comparison with APS001b, APS001, or S-eCD. Densitometric analysis also indicated that the signals from the stationary phase were reduced to 50-75% in comparison with those at log phase for APS001b, APS001, and S-eCD. These results suggest that the CD protein is not replenished with newly expressed CD protein, and/or that its degradation is promoted in the stationary phase. Fig. 2 . Western Blotting of CD Protein. The total proteins from each plasmid transformant at various growth phases were separated by SDS-PAGE, and CD protein was detected using anti-cytosine deaminase antibody. The samples were adjusted to 0.25 mg proteins per lane.
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Measurement of 5-FC to 5-FU conversion with bacterial incubation
We estimated CD enzymatic activity for 5-FC to 5-FU by measuring the accumulation of 5-FU during culture (Fig. 3A) . The results indicated that APS001b can produce larger amounts of 5-FU than APS001 or S-eCD. The ratio of the difference in amount of 5-FU accumulation as between APS001b and APS001 was 2.2 (1.8-2.5). Taken together, these results confirm that CD mutant D314A shows 2.2-fold higher enzymatic activity for conversion of 5-FC to 5-FU than native CD when it is expressed in B. longum cells.
Moreover, the converted 5-FU concentrations increased linearly from 0-8 h in S-eCD and APS001 and in APS001b. From 8-24 h, 5-FU concentrations increased gradually, while no 5-FU was detected in wild-type B. longum. This difference is caused by the pH change due to production of lactic acid and acetic acid by A, Each strain was adjusted to 5 Â 10 8 cfu and 5-FC was added to the culture medium, followed by incubation at 37 C in an anaerobic system. The 5-FU concentration was measured after 0, 2, 4, 8, 18, and 24 h. B, Viable cell counts were achieved with 5 BL agar plates at 0, 3, 6, 9, 12, 15, 18, 21 and 24 h after the incubation. , APS001b; , APS001; , S-eCD; , B. longum (WT).
Bifidobacterium. After 24 h of incubation, the pH of the medium had fallen to less than 4.2 from the initial value of about 6.0.
On the other hand, the growth rates of these three transformants were almost identical to those of nontransformed parental B. longum 105A (Fig. 3B) . These results suggest that newly constructed pAV001-HU-eCD and pAV001-HU-eCD-M968 are maintained stably in B. longum, and that the plasmids are not hazardous to the host cells.
In vitro 5-FC to 5-FU conversion assay The above experiment for comparison of CD enzymatic activity by incubation of viable bacterial cells and 5-FC revealed that living Bifidobacterium transformed with the CD mutant D314A deaminated 5-FC to 5-FU, and that the CD mutant D314A was superior to native CD with regard to 5-FC to 5-FU conversion activity. However, the comparison of CD enzymatic activity by conversion of 5-FC to 5-FU by viable B. longum cells was not suitable for comparative analysis due to difficulty in adjusting cell numbers until logistic cell growth, differences in promoter activity depending on the growth phase, pH changes, and so on. Enzymatic comparative analysis must be done under simple experimental conditions with excess substrate and short reaction times to avoid inactivation of the enzyme. To estimate the enzymatic activities of the mutant and the native CD, protein extracts from wild-type Bifidobacterium and transformants were analyzed.
The protein extracts were adjusted to 5 mg protein/ tube, and the reaction time was 20 min. The results showed that the CD mutant D314A (APS001b) was able to produce 5-FU 12.4-24.3 mM (/g protein/min), while the levels produced by the native CD were 1.0-2.6 mM (APS001) and 1.1-2.5 mM (S-eCD). Thus, the CD mutant D314A had 9.3-12.4 (average 10.9)-fold greater 5-FC deamination activity than native CD (APS001). Comparisons were done among different growth phases. Activity was highest in log phase cells, while that at stationary phase was reduced by 50%. The same tendency was also observed in native CD transformants (Fig. 4) . Briefly, CD mutant D314A activity was almost 10-fold higher than that of the native CD with regard to the 5-FC deamination rate, which means that APS001b is superior to APS001 and S-eCD with regard to the utilization of 5-FC.
Plasmid segregational stability
The segregational stabilities of pAV001-HU-eCD-M968, pAV001-HU-eCD, and pBLES100-S-eCD in B. longum were examined, since stable maintenance of the recombinant plasmid is very important for gene expression. APS001b, APS001, and S-eCD were cultured in the presence of SPCM. The cells were then diluted and incubated in MRS broth without SPCM. As shown in Fig. 5 , more than 80% of the cells showed the SPCMresistant phenotype after 3 d in subculture, indicating that more than 80% of the cells maintained plasmids pAV001-HU-eCD-M968 and pAV001-HU-eCD stably after 30 generations. In addition, more than 60% of pBLES100-S-eCD-transformed B. longum showed the SPCM-resistant phenotype after 30 generations. These results suggest that the plasmid segregational stability of pAV001-HU-eCD-M968-and of pAV001-HU-eCDharboring B. longum is almost the same or slightly better than that of pBLES100-S-eCD. The lysate proteins from each strains were adjusted to 5 mg and incubated with 40 mM 5-FC at 60 C for 20 min accurately. The reaction was stopped rapidly with 0.5 M trichloroacetic acid, and 5-FU production was measured by HPLC.
Discussion
The results of the present study indicate that the reconstitution of the shuttle-plasmid carrying the mutant E. coli CD gene was successful despite the first attempt to express the CD mutant D314A in another organism. The novel shuttle-plasmid pAV001-HU-eCD-M968 can be transformed into the cells, is maintained stably, and expresses the CD mutant D314A in B. longum. It is notable that B. longum harboring the novel plasmid can utilize 5-FC at a rate 10-fold higher than the previously reported shuttle-plasmid, pBLES100-S-eCD. In our studies, the results of CD assays from conversion of 5-FC to 5-FU by viable B. longum cells and in vitro 5-FC to 5-FU conversion assay appear to be inconsistent. As shown in Fig. 3A , the mutant's enzymatic activity was enhanced by 2 to 3-fold in culture. On the other hand, it was enhanced by almost 10-fold in the in vitro assay, as shown in Fig. 4 . This difference was due to the pH change caused by the production of lactic acid and acetic acid by Bifidobacterium in the study of the conversion of 5-FC to 5-FU by viable B. longum cells. Bacterial CD is a stable protein, and its enzymatic activity remains unchanged over a wide range from neutral to weekly alkaline pH (pH 6.5 to 9.0). 29) However, in the study of the conversion of 5-FC to 5-FU by viable B. longum cells, the pH change was from 6.0 to 4.0. Therefore, the conversion of 5-FC to 5-FU by viable B. longum cells did not show true enzymatic ability, and hence the in vitro 5-FC to 5-FU conversion assay reflected these abilities more accurately.
The kinetics of wild-type and mutant CD (D314A) were investigated in detail by Mahan et al. 21, 22) They reported only a 2.2-fold enhancement of the K cat =K m value for 5-FC, with values of 50 (s-1/mM) and 23 for mutant and native CD respectively. Our results indicate that the effect of the mutation was almost 10-fold greater than that mentioned above. It is possible that these discrepancies were due to differences in species used (E. coli vs. B. longum) and to the expression system (B. longum expressed CD as fusion protein fused to a 9-amino acid region of HU protein at its N-terminal in the previous study). 17) The segregational stability of the pAV001 series in B. longum (APS001, APS001b) was almost same as compared that of previous shuttle-plasmid, pBLES100-S-eCD (S-eCD) (Fig. 5) . The antitumor efficacy is dependent on the stability of the recombinant construct and on efficient expression of the therapeutic genes in an in vivo tumor system. Our previous studies indicated that B. longum can maintain a population of 10 6 -10 8 cfu per 1 g of tumor tissue after i.v. inoculation. 12) About 20 generations are needed to reach 10 6 cfu, and about 27 generations to reach 10 8 cfu. The results of the present study indicate a maintenance rate of 84% after 30 generations, which is beyond the minimum requirement. These results strongly suggest that B. longum expressing mutant CD D314A exhibits powerful anti-tumor efficacy after systemic administration of 5-FC, similarly to local injection of 5-FU into the tumor. In addition, the use of B. longum in cancer therapy can result in the maintenance of a good quality of life for patients because of the reduced side effects of anti-cancer agents and reduced anaphylaxis and toxicity as compared to other anaerobic bacteria. Experiments are now in progress to analyze the effectiveness of B. longum harboring pAV001-HU-eCD-M968 (APS001b) in an in vivo rodent tumor model. This novel approach to tumor targeting using BifidobactErial Selective Targeting-Cytosine Deaminase (BEST-CD) therapy might also be useful with metastatic cancer patients as systemic disease patients. Plasmid stability in B. longum 105A was examined under continuous culture carried out without selective pressure. Samples were diluted and plated onto BL plates with and without spectinomycin. The plasmid maintenance ratio (%) is represented by the formula (average number of colonies on BL plates with spectinomycin)/(average number of colonies on BL plates without spectinomycin). , APS001b; , APS001; , S-eCD.
